-
1دورية أكاديمية
المؤلفون: Seyed Mohammadali Dadfar, Denise Camozzi, Milita Darguzyte, Karolin Roemhild, Paola Varvarà, Josbert Metselaar, Srinivas Banala, Marcel Straub, Nihan Güvener, Ulrich Engelmann, Ioana Slabu, Miriam Buhl, Jan van Leusen, Paul Kögerler, Benita Hermanns-Sachweh, Volkmar Schulz, Fabian Kiessling, Twan Lammers
المصدر: Journal of Nanobiotechnology, Vol 18, Iss 1, Pp 1-13 (2020)
مصطلحات موضوعية: Iron oxide nanoparticles, SPION, MRI, MPI, Hyperthermia, Biotechnology, TP248.13-248.65, Medical technology, R855-855.5
وصف الملف: electronic resource
Relation: https://doaj.org/toc/1477-3155
-
2دورية أكاديمية
المؤلفون: Tjalf Ziemssen, Frank Hoffmann, Stephan Richter, Ulrich Engelmann, Robin White
المصدر: Frontiers in Neurology, Vol 12 (2021)
مصطلحات موضوعية: alemtuzumab, non-interventional study, risk-management plan, Germany, real world data, multiple sclerosis, Neurology. Diseases of the nervous system, RC346-429
وصف الملف: electronic resource
-
3دورية أكاديمية
المؤلفون: Boris A. Kallmann, Stefan Ries, Jennifer S. Kullmann, Laura M. Quint, Ulrich Engelmann, Andrew Chan
المصدر: Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
مصطلحات موضوعية: Neurology. Diseases of the nervous system, RC346-429
وصف الملف: electronic resource
Relation: https://doaj.org/toc/1756-2864
-
4دورية أكاديمية
المصدر: Therapeutic Advances in Neurological Disorders, Vol 12 (2019)
مصطلحات موضوعية: Neurology. Diseases of the nervous system, RC346-429
وصف الملف: electronic resource
Relation: https://doaj.org/toc/1756-2864
-
5
-
6
-
7
المؤلفون: Ulrich Engelmann, Stephan Richter, Tjalf Ziemssen, Robin White, Frank Hoffmann
المصدر: Frontiers in Neurology, Vol 12 (2021)
Frontiers in Neurologyمصطلحات موضوعية: safety, 0301 basic medicine, medicine.medical_specialty, CD52, effectiveness, multiple sclerosis, 03 medical and health sciences, 0302 clinical medicine, Natalizumab, Internal medicine, Germany, medicine, alemtuzumab, Glatiramer acetate, RC346-429, Original Research, Expanded Disability Status Scale, business.industry, Multiple sclerosis, Interim analysis, medicine.disease, Fingolimod, risk-management plan, real world data, 030104 developmental biology, Neurology, Alemtuzumab, Neurology. Diseases of the nervous system, Neurology (clinical), business, 030217 neurology & neurosurgery, non-interventional study, medicine.drug
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc1f4d7ca539bef71144661091f9ad4f
-
8
المؤلفون: Stefan Ries, Ulrich Engelmann, Jennifer S Kullmann, Boris Kallmann, Laura M Quint, Andrew T. Chan
المصدر: Kallmann, Boris A; Ries, Stefan; Kullmann, Jennifer S; Quint, Laura M; Engelmann, Ulrich; Chan, Andrew (2021). Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status. Therapeutic advances in neurological disorders, 14, p. 17562864211005588. Sage 10.1177/17562864211005588 <http://dx.doi.org/10.1177/17562864211005588>
Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
Therapeutic Advances in Neurological Disordersمصطلحات موضوعية: 0301 basic medicine, Pre treatment, medicine.medical_specialty, 610 Medicine & health, multiple sclerosis, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Teriflunomide, medicine, observational, RC346-429, Original Research, Pharmacology, immunosenescence, treatment, business.industry, Multiple sclerosis, satisfaction, Immunosenescence, medicine.disease, pre-treatment, switch, 030104 developmental biology, Neurology, chemistry, Relapsing remitting, age, Observational study, Neurology (clinical), Neurology. Diseases of the nervous system, Once daily, business, 030217 neurology & neurosurgery
وصف الملف: application/pdf
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75354bdb730ef84846d2d7012b1034a2
https://boris.unibe.ch/157488/1/Kallmann__2021__Teriflunomide_in_relapsing_remitting_MS.pdf -
9كتاب إلكتروني
-
10
المصدر: Kallmann, Boris A; Tiel-Wilck, Klaus; Kullmann, Jennifer S; Engelmann, Ulrich; Chan, Andrew (2019). Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study. Therapeutic advances in neurological disorders, 12, p. 1756286419835077. Sage 10.1177/1756286419835077 <http://dx.doi.org/10.1177/1756286419835077>
Therapeutic Advances in Neurological Disorders, Vol 12 (2019)
Therapeutic Advances in Neurological Disordersمصطلحات موضوعية: medicine.medical_specialty, patient-related outcomes, 610 Medicine & health, multiple sclerosis, lcsh:RC346-429, 03 medical and health sciences, chemistry.chemical_compound, oral, 0302 clinical medicine, Internal medicine, Teriflunomide, Medicine, In patient, 030212 general & internal medicine, Immunomodulatory Agent, observational, lcsh:Neurology. Diseases of the nervous system, Original Research, Pharmacology, treatment, business.industry, Multiple sclerosis, medicine.disease, Neurology, chemistry, Observational study, Neurology (clinical), business, 030217 neurology & neurosurgery
وصف الملف: application/pdf
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d01af5e2a83cbf36fd8e732d9c562c8